Stock Alerts
Nice bounce today but I’m buying FCX puts in my Volatility Portfolio for more downside ahead
Last night I played standard first-stage defense by selling shares of Freeport McMoran Copper and Gold (FCX) out of my Jubak's Picks Portfolio. That reduces, in my opinion, my risk to the likely continuation (again in my opinion) of a market retreat on fear that the...
Selling copper pick Freeport McMoran on fears of U.S./China tariff war
Freeport McMoRan Copper and Gold (FCX) was the third and last copper stock I added to my portfolios back in January 12, 2018--after Southern Copper (SCCO) and First Quantum Minerals (FQMLF). I added so much copper since copper prices were soaring in 2017--up 30%--and...
Amazon tanks after report that President Trump wants to “go after” the company
Well, why not? Shares of Amazon (AMZN) were down as much as 7.4% after Axios reported that President Donald Trump is "obsessed" with regulating the company and has discussed changing the way the company collects (or doesn't) sales tax. The stock rallied back to close...
Little spillover (yet) from Concho acquisition of Permian producer RSPP
Today Concho Resources (CXO) announced the acquisition of RSP Permian (RSPP) to create the biggest  oil and natural gas producer from the shales of the Permian Basin. The $9.5 billion all stock deal represents a 29% premium to the Tuesday close for RSP Permian. That...
Good news for Brazilian ETFs EWZ and EWZS: Central bank cuts interest rates again and signals that it’s not done either
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Adding Independent Bank to my Dividend Portfolio
Just in case you haven't noticed, it's really, really hard at the moment to find a decent dividend yield in a stock that doesn't require taking on substantial risk. That's what happens when you've got elevated asset prices after a long rally, a still-low interest rate...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Leveraging near-term Incyte catalysts by adding call options to Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out--results from critical drug trials weren't likely to be reported for two years. The reason to hold onto...
Selling Acadia Pharmaceuticals out of my Jubak Picks portfolio
Today I'm selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective for...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...Jim’s Stock Alerts
Download Jim’s eBook for Free
